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Abstract 
The purpose of the study was to investigate the efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. 
The primary objective of this trial was to assess the clinical efficacy and safety of a 10-days course of therapy with a daily 
administration of Cerebrolysin (50 mL IV per day). The trial had to demonstrate that Cerebrolysin treatment is safe in hemorrhagic 
stroke. 
Methods: The study was performed as a prospective, randomized, double blind, placebo-controlled, parallel group study 
with 2 treatment groups. Efficacy measures were the Unified Neurological Stroke Scale, Barthel Index, and Syndrome Short Test. 
The duration of the trial was of 21 days for each patient. Out of 100 randomized patients, a total of 96 (96%) completed the study. 
Results: Overall, no statistically significant group effects were observed based on single average comparisons at the 
individual visits. It could be shown that the treatment of hemorrhagic stroke with Cerebrolysin is safe and well tolerated. 
Conclusion: In the changes of UNSS, BI and SST from baseline to day 21, the group differences are not statistically 
significant; however, the use of Cerebrolysin in hemorrhagic stroke is safe and well tolerated and studies with a larger sample size 
may provide statistical evidence of Cerebrolysin’s efficacy in patients with hemorrhagic stroke. 
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Introduction  
The stroke is a major cause of mortality and 
disability, being responsible for about five million deaths 
worldwide each year [1]. Epidemiological data indicate 
that only cardiac disorders and cancer are the most 
common causes of mortality in Europe. The dramatic 
impact of stroke, on individuals, families and healthcare 
resources, is heightened by the long-term and frequently 
debilitating nature of its effects on mental and physical 
function and by its strong tendency to recur. Thereby, 
hemorrhagic stroke accounts for approximately 13% of all 
stroke incidences. However, taking a closer look at the 
stroke epidemiology, rates of ischemic and hemorrhagic 
stroke are higher in eastern than in Western Europe, 
North America or Australia [2], [3]. The incidence of 
stroke, in particular hemorrhage, is especially high in 
eastern Asia. In this area of the world stroke is the leading 
cause of death. Approximately 27% of strokes were 
secondary to hemorrhage. In eastern Asia, the relative 
proportion of hemorrhagic stroke is higher than that in 
other parts of the world [4]. The mortality rate in patients 
with hemorrhagic stroke is approximately four times 
higher than in patients with ischemic stroke [5], [6]. Only 
38% of hemorrhagic stroke patients survive beyond the 
first year [7]. The management of patients with 
hemorrhagic stroke is generally limited to the supportive 
care or evacuation of the hematoma, although the efficacy 
of the surgical removal is variable and controversial [8], 
[9], [10]. 
Therefore, the need for a safe and effective 
treatment for patients with hemorrhagic stroke is urgently 
needed. There has been much interest in drugs that 
potentially protect neurons from the effects of ischemia, 
like NMDA receptor antagonists, antibodies to adhesion 
molecules, free radical scavengers, gangliosides, and 
apoptosis inhibitors. Encouraging results derive from 
studies in cell culture and in vivo stroke models after 
treatment with Cerebrolysin. The pre-clinical profile and 
the results of the previous clinical trials, provide the 
rationale for the assessment of the effects of Cerebrolysin 
treatment in patients with acute ischemic stroke and acute 
cerebral hemorrhage. 
Cerebrolysin is a brain derived peptide 
preparation produced by a standardized enzymatic 
breakdown of lipid-free brain proteins and consists of low 
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molecular weight peptides and free amino acids. It has 
been used in a number of European and Asian countries 
for various indications, for many years, having only rare 
and benign side effects reported. Cerebrolysin shows 
promise as a treatment for patients with an acute 
ischemic stroke. The effects of Cerebrolysin can be 
explained by its neuroprotective [11] and neurotrophic 
action [12], [13].  
Data from earlier studies indicated a consistent 
trend in favor of Cerebrolysin as a treatment in patients 
suffering from an ischemic stroke [14], [15], [16], [17]. 
The first pilot trial indicated that Cerebrolysin 
could safely be used in cases of hemorrhagic stroke with 
a potentially beneficial clinical outcome [18]. 
The primary objective of this trial was to assess 
the safety and clinical efficacy of a 10-days course of 
therapy with a daily administration of Cerebrolysin (50 mL 
IV per day).  
Methods and Materials 
Study design 
The design used in this study fulfilled all 
methodological requirements in order to prove the safety 
of a new treatment. The study was performed as a 
prospective, randomized, double blind, placebo-
controlled, parallel group study with 2 treatment groups. In 
terms of ethical considerations, the treatment of all 
patients followed the guidelines regarding the standard 
treatment for cerebral hemorrhage. Four evaluation visits 
were scheduled for the enrolled patients. The patients 
were screened for study entry within 24 h from the onset 
of stroke. Eligible patients were then randomized to one of 
the two treatment groups and received the baseline 
evaluation of the efficacy outcome measures (visit 1, day 
1). Immediately after the screening and baseline 
evaluation, patients received the first i.v. infusion of study 
medication. One group received 50 ml Cerebrolysin 
(n=51) the other group 50 ml placebo (n=49) for 10 
consecutive days. Additional safety and clinical efficacy 
visits were scheduled on: day 4 (visit 2), day 10 (visit 3, 
end of active treatment) and on day 21 (visit 4). 
The study was conducted at the University 
Hospital Bucharest, Department of Neurology. All patient 
data was collected at this single study center. The study 
was performed according to ICH-GCP guidelines and to 
the declaration of Helsinki and the protocol was approved 
by the national and local ethics committee of the study 
site. All patients and/or their relatives signed an informed 
consent form prior to the participation in the clinical study. 
The patients were recruited between December 2003 and 
April 2007. 
 
In- and exclusion criteria 
The patient had to be between 40 and 85 years 
old (both inclusive) with a diagnosis of a first hemorrhagic 
stroke in the basal ganglia. The initial treatment with the 
trial treatment had to be administered between 6 and 24 
hours after onset of symptoms. 
Patients had to be excluded if a complete 
remission of symptoms occurred within the first few hours 
after stroke (i.e. patients who suffered from a TIA) or if the 
ischemic stroke or hemorrhagic stroke occurred in brain 
areas other than the basal ganglia, including the presence 
of the blood into the ventricles). 
Furthermore, exclusion was necessary if the 
patient had uncontrollable hypertension (above 200/100 
mmHg), an acute myocardial infarction, congestive heart 
failure, moderate to severe dementia prior to stroke, coma 
or stupor, accompanying severe diseases (cancer etc.), 
history of a stroke or other neurological disorders which 
impair evaluation. Other exclusion criteria were pregnancy 
or patients in lactation period, patients participating in 
other clinical trials, patients with chronic hepatic disorders 
or renal disorders/impaired renal function with serum 
creatinine above 1.5 mg/dl. 
Patients were not included if he/she or his/her 
relatives refused to participate in the clinical trial. 
 
Patient population 
The trial was conducted in subjects suffering 
from first hemorrhagic stroke in the basal ganglia. The 
diagnosis of the hemorrhagic stroke was confirmed by 
Tomodensitometry (TDM). A total of 100 patients was 
randomized in the study and 96 patients (96%) completed 
the study. 49 patients received Placebo and 51 patients 
Cerebrolysin, out of which there were 62% male and 28% 
female patients with an average age of 65 years old. 
Efficacy measures were the Unified Neurological Stroke 
Scale, Barthel Index, and Syndrome Short Test. The 
duration of this trial for each patient was of 21 days. On 
inclusion day (visit 1) each subject received a baseline 
evaluation. The assessments and TDM were repeated on 
days 10 and 21.  
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Treatment and Randomization 
Cerebrolysin 50 mL or placebo were 
administered once daily for 10 days by IV infusion in a 
peripheral vein.  
The study medication was provided by EBEWE 
Pharma and was packaged in amber glass vials 
containing 100 mL ready-to-use infusion solutions 
containing 50 mL Cerebrolysin and 50 mL normal saline 
(0.9% NaCl). The placebo infusion consisted of 100 mL of 
normal saline (0.9  NaCl). Both, active and control 
medication was packaged in 100 mL amber glass vials 
and were indistinguishable in appearance. Patients who 
met all inclusion criteria were assigned to one of the 
treatment groups in a 1:1 ratio according to a 
randomization code generated by computer software 
(EBEWE Pharma, Unterach, Austria). The investigators 
and all the study personnel were blind as to the random 
code assignment until the statistical analysis was 
finalized. A sealed envelope with information on the actual 
treatment for each patient was provided to the 
investigators for emergency cases.  
The dosage of Cerebrolysin in this study was 
chosen according to the clinical experience and was 
similar to the range of dosages used in previous clinical 
trials [19], [20]. 
 
Safety evaluation 
Adverse events (AE) and laboratory tests (blood 
chemistry, hematology and urinalysis) were evaluated for 
emergence of abnormal laboratory findings or changes in 
clinical laboratory tests and seriousness. Furthermore, 
changes in vital signs and general physical and 
neurological examinations were evaluated to determine 
the safety of Cerebrolysin. AEs were rated by the 
investigator as mild, moderate or severe. The relationship 
to the study drug was also rated by the investigator. The 
rating was done under blinded conditions. The patient’s 
vital signs were measured at all visits, and a record of any 
adverse events was made. Additionally, an ECG was 
performed. A TDM was performed at visit 1 and 3 in order 
to determine the infarct volume.  
 
Statistical analysis 
An exploratory approach to the efficacy data was 
also used. Comparisons between groups at baseline were 
performed to warrant validation of proper randomization. 
This is defined as not exceeding a nominal two-sided 10% 
level of statistical significance. Kruskal Wallis H-tests 
followed at each visit, in case of statistical significance at 
the nominal two-sided 5% level by Wilcoxon Mann 
Whitney U-tests. At the same level, there is an 
appropriate method for an acceptable balance between 
rigid confirmatory objectives and power and sensitivity 
considerations in the context of the available sample 
sizes. Analysis of a one-way analysis of variance as a 
control was presented as an additional validation tool. 
This validation tool is essential to warrant a satisfactory 
quality control of the H-test and U-test methodology, 
based on discrete data as all those clinical scores are.  
The comparison between the two groups 
regarding the background and demographic 
characteristics was assessed by the use of descriptive 
statistics and appropriate parametric and non-parametric 
tests. Since this was an exploratory study, no calculation 
for the sample size has been performed. The sample size 
has been chosen according to experiences of previous 
clinical studies using Cerebrolysin. 
All statistical analyses are based on the 
observed data set of the cases, and no imputation (e.g. 
last observation carried forward etc.) was performed. The 
statistical analysis was carried out by Neumann and 
Team, Vienna, Austria, by using a proprietary statistical 
software. This software has been tested and validated 
according to current guidelines.  
 
Efficacy measurement methods 
Changes from baseline (visit 1) to day 21 (visit 4) 
were used to assess the efficacy on the Unified 
Neurological Stroke Scale (UNSS), Barthel Index (BI), 
and Syndrome Short Test (SST). Efficacy measurements 
were performed at visits 1, 2, 3, and 4. 
Visit 2 was performed on day 4 after Baseline. 
Visit 3 was performed at the end of the treatment on day 
10, visit 4 on day 21.  
Results 
Patient disposition 
100 patients were randomized to the two 
treatment groups. 51 were allocated to the Cerebrolysin 
group and 49 to the control group. These 100 patients 
constituted the ITT population. Of these patients, 96 
completed the study, 48 in the Cerebrolysin group and 46 
in the control group. The reasons for discontinuation were 
1 adverse event (skin rash) in the placebo group, 2 cases 
of death in each group and 1 case of consent withdrawal 
in the Cerebrolysin group. There were no obvious 
differences between the treatment groups with regard to 
the reason of study termination. 
 
Demographic data and baseline 
characteristics 
Baseline demographic of the patients is 
presented in Table 1. No significant group differences of 
the demographic characteristics were observed at 
baseline. Heterogeneities at baseline variables are 
presented in Table 2 and a comparison of the efficacy 
parameters at baseline is given in Table 3. Patients in the 
Placebo group had a slightly better result in the Barthel 
Index at baseline. 
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  Cerebrolysin  Placebo 
  N=51  N=49 
Gender 
  M a l e  
  F e m a l e  
 
31 
20 
 
31 
18 
Age (years)  65  65 
Height (cm)  168  168 
Weight (kg)  73  76 
 
The following variables displayed some 
statistically significant heterogeneities at the nominal 5% 
level at the baseline visit:  
 
 
 
 
  Cerebrolysin  Placebo 
variable  N=51  N=49 
number of daily smoked  
cigarettes, mean 
23  11 
number of alcohol units/week,  
mean 
11  7 
heart rate, mean  80  76 
respirations/min, mean  20  18 
% abnormal pulmonary med.  
history 
0%  10% 
% history of alcohol, drug abuse  59%  22% 
RBC, mean  4,7  4,9 
% neutrophils, mean  78%  72% 
Bicarbonate HCO3, mean  24  25 
severity of first adverse event,  
% mild 
87%  64% 
 
Heart rate and respiration, as well as some other 
baseline variables shown in Table 2 were significantly 
different in the two groups at baseline. Diagnostic 
parameters as well as the severity of the disease were 
comparable across treatment groups. Furthermore, no 
relevant group differences were observed in demographic 
parameters, laboratory assessments, physical 
examinations and medical history of the patients. 
 
 
 
  Cerebrolysin  Placebo  Total 
  50 mL     
  N=51  N=49  N=100 
SST results at 
Baseline,  
mean 
21.725 ± 6.65  20.429 ± 7.40  21.090 ± 7.02 
UNSS Index 
at Baseline,  
mean 
38.725  ± 16.80  37.583  ± 21.06  38.172  ± 18.89 
BI Index at 
Baseline,  
mean 
23.431  ± 16.51  28.469  ± 21.07  25.900  ± 18.95 
N = number of patients 
Values are mean ±  standard deviation; ITT dataset 
 
 
 
  Cerebrolysin  Placebo  Total 
  50 mL     
  N=49  N=42  N=91 
Tomodensitometry 
at Baseline, mean  14,29 ± 11,76  11,61 ± 9,25  13,11 ± 10,80 
N = number of patients 
Values are mean ±  standard deviation; ITT dataset 
 
From the statistical perspective, the two study 
therapy groups did not show any indications for some 
statistically significant group effects at the nominal 5% 
level of significance and, therefore, all the discrepancies 
which were observed, can be most likely attributed to the 
sampling error. 
The SST results at baseline were comparable at 
baseline visit. The mean result for Cerebrolysin patients 
(n=51) was 21.725 ± 6.65 compared to 20.429 ± 7.40 for 
patients treated with placebo (n=49). 
The UNSS results at baseline showed no 
significant differences at baseline as well. Patients treated 
with Cerebrolysin had a mean UNSS index of 38.725 ± 
16.80 compared to 37.583  ± 21.06 in patients treated 
with placebo. 
BI at baseline showed the following mean 
results: 23.431 ± 16.51 in patients treated with 
Cerebrolysin and 28.469  ± 21.07 in placebo treated 
patients.  
The tomodensitometry data, which were 
calculated in a post-hoc analysis, did not show any 
significant differences between the two groups at 
baseline, with 14,29 ± 11,76 cm3 in the active group and  
11,61 ± 9,25 cm3 in the control group.  
 
Efficacy 
The efficacy was assessed by using the Short 
syndrome test, the Unified neurological stroke scale and 
the Barthel Index.  
Cognitive changes were assessed by using the 
SST. The change of SST from baseline to day 21 (visit 4) 
was 6.83 ± 6.71 and 4.39 ± 5.56 in the Cerebrolysin and 
placebo group, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tabel 1 Demographic data Disorders 
Tabel 2 Heterogeneities at baseline variables 
Tabel 3 Efficacy parameters at baseline 
Tabel 4 Tomodensitometry data at baseline 
SST total score
0
5
10
15
20
25
02468 1 0 1
days
a
v
e
r
a
g
e
2
Cerebrolysin placebo
Fig. 1  Change in SST total score over time Journal of Medicine and Life Vol. 3, No.2, April‐June 2010  
Neurological deficits were assessed by using the 
UNSS. The change in the UNSS total score from baseline 
to day 21 (visit 4) was 22.44 ± 12.83 in the Cerebrolysin 
and 23.98 ± 13.04 in the placebo group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The BI was used to assess the performance in 
basic activities of daily living. Over time, the BI score in 
the Cerebrolysin group changed by 27.81 ± 20.29 and in 
the control group by 29.67 ± 15.03. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, there were no statistically significant 
group effects observed based on single average 
comparisons between the individual visits. 
None of the in-between therapy group 
comparisons showed statistically significant group effects 
at the nominal 5% level, nor in the evaluation of changes 
also after a baseline adjusted analysis of covariance.  
In a post hoc analysis, the decrease in volume of 
the hemorrhage was calculated.  
 
 
 
Table 1 Change in volumetry of hemorrhage over time (in cm3) 
  Day 1  Day 10  Day 21 
Cerebrolysin  14,29 ± 11,76  10,92 ± 12,21  2,48 ± 4,62 
Placebo  11,61 ± 9,25  9,32 ± 9,32  6,53 ± 6,53 
UNSS total score
0
10
20
30
40
50
60
70
0 5 10 15 20 25
day
a
v
e
r
a
g
e
Cerebrolysin placebo
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2  Change in volumetry of hemorrhage over time 
Fig. 2  Change in UNSS score over time 
 
Although the hemorrhage size was a little bit 
larger at day 1 in the Cerebrolysin group, the reduction in 
volume was slightly better on day 10 but distinctively 
better on day 21. A faster reduction in the hemorrhage 
size may contribute to a faster recovery in patients with 
hemorrhagic stroke.   
Barthel Index  total score
0
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Safety Results 
The analysis of the Safety parameters showed 
that Cerebrolysin treatment with up to 50mL per day does 
not increase the incidence of the treatment’s emergent 
adverse events as compared to the Placebo treatment. 
The analysis of the lab parameters, vital signs and ECG 
examinations did not provide any evidence for any 
substance specific toxic effect of Cerebrolysin. The 
treatment with Cerebrolysin® with doses up to 50mL is 
safe and well tolerated. 
The most common adverse event reported was 
urinary infection with 13 (25.5%) and 14 (28.6%) 
occurrences in the Cerebrolysin group and the placebo 
group, respectively. This was followed by increased body 
temperature with 10 (19.6%) and 8 (16.3%) occurrences 
in the Cerebrolysin and placebo group, respectively. 
Constipation occurred in 5 cases (9.8%) of the 
Cerebrolysin group and 9 cases (18.4%) of the placebo 
group. High blood pressure was reported in 6 (11.8) and 5 
(10.2) patients of the Cerebrolysin and placebo group, 
respectively. Hypernatremia and Hypokalemia occurred in 
6 (11.8%) patients of the Cerebrolysin group, but only 2 
(4.1%) patients in the placebo group experienced 
Hypokalemia. There was no Hypernatremia reported in 
Fig. 3  Change in BI score over time 
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the Placebo group. All other individual events occurred 
less than 6 times across all study groups. Otherwise, 
there was no difference between the treatment groups as 
far as the incidence of the individual adverse events and 
the adverse events observed did not point to any 
substance related toxic effect of Cerebrolysin. 
In total, 5 (5% out of 100) patients experienced 
at least one serious adverse event. This included 3 (3%) 
and 2 (2%) patients treated with placebo and 
Cerebrolysin, respectively. Overall, the incidence of SAEs 
was comparable in the two study groups.  
Only one patient (patient 144) discontinued the 
study due to AE (allergic skin rash). The investigational 
drug was stopped from being administered after the 
discontinuation of Ciprofloxacin did not improve the 
allergic reaction. 
Among all cases, no patient receiving 
Cerebrolysin® had severe adverse events, which were 
probably related to the treatment. One patient receiving 
Placebo experienced an allergic skin reaction, which was 
determined as possibly being related to the study drug. 
Because the allergic reaction did not stop after the 
discontinuation of Ciprofloxacin, the study drug was 
discontinued as well, and the event was considered to be 
possibly related to the study drug.  
For all other adverse events, the investigators 
assumed no causal relationship to the study medication. 
In accordance with this judgment, it can reasonably be 
assumed that none of the cases were caused by 
Cerebrolysin® or Placebo.  
None of the events were repeatedly reported and 
they occurred with equal frequency in both treatment 
groups. There is no indication of any substance-specific 
effects of Cerebrolysin. 
Overall, the number of SAEs was very low, given 
the indication of use in this study. None of the patients 
suffered a fatal SAE. The reason may be the fact that 
patients with very severe symptoms were excluded from 
the study. Therefore, the safety results were good in both 
groups and the primary endpoint, the safety of 
Cerebrolysin in hemorrhagic stroke could be proven. 
Discussion 
In the changes of UNSS, BI and SST from 
baseline to day 21, the in-between group differences were 
not statistically significant; however, the use of 
Cerebrolysin in hemorrhagic stroke is safe and well 
tolerated and studies with a larger sample size may 
provide statistical evidence of Cerebrolysin efficacy in 
patients with hemorrhagic stroke. 
Further dosage optimization could lead to further 
improvements of Cerebrolysin therapy. 
Analysis of the Safety parameters showed that 
Cerebrolysin treatment with up to 50mL per day did not 
increase the incidence of Treatment Emergent Adverse 
Events as compared to Placebo treatment. The analysis 
of the lab parameters, vital signs and ECG examinations 
did not provide any evidence for any substance specific 
toxic effect of Cerebrolysin. 
The treatment with Cerebrolysin® with doses up 
to 50mL is safe and well tolerated. 
The safety statement seems to be important for 
future, larger phase IV studies due to the fact, that this 
study data is the body of evidence that the safety profile 
of Cerebrolysin, under a homogenous set of concomitant 
medications and diseases is overall very well. 
Further studies with a higher number of patients 
seem to have good chances to extend the findings of this 
trial and to experience positive results in the efficacy of 
Cerebrolysin in patients with hemorrhagic stroke. 
Therefore, patients with severe symptoms should be 
included in further studies to prove positive effects of 
Cerebsolysin. 
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